ASCO 2023 | Beyond tissue biopsies: liquid biomarkers in melanoma

Helen Rizos, PhD, Macquarie University, Sydney, Australia, discusses the take home messages from her presentation on the clinical value of cell-free DNA in patients with melanoma. Prof. Rizos highlights that although circulating tumor DNA (ctDNA) is valuable in predicting melanoma prognosis, its lack of sensitivity in early-stage melanoma patients serves as a limitation of its use. Furthermore, the possibility exists that these technologies may start to detect mutations associated with ageing rather than cancer as they become more advanced. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.